Expert insights. Personalized for you.
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen MORE
Credit: Surajit Chatterjee To better understand how RNA in bacteria gives rise to protein–and along the way, target these processes in the design of new antibiotics–researchers are turning their attention to the unique way this process happens in bacteria. MORE
Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Oversubscribed round enables late-stage clinical development of lead … Continue reading → Business Wire MORE
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs MORE
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India Vaccine Would Be India’s First Indigenous RNA Vaccine, Exemplifying HDT … Continue reading → Business Wire MORE
That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey "For the first time in history, medicine has become information." MORE
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on. MORE
Oncotarget published “Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection” which reported that in case of bladder cancer, […]. MORE
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: RNA-targeting enzyme expands the CRISPR toolkit.Researchers at MIT’s McGovern Institute for Brain Research have discovered a bacterial enzyme that they say could expand scientists’ CRISPR toolkit, making … Continue reading → #news MORE
?The partnership combines the companies' resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner MORE
With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease. MORE
16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com 16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “16S Ribosomal RNA (16S rRNA) – Drugs in Development, 2021” … Continue reading → Business Wire MORE
Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form. MORE
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines MORE
billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization. MORE
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology.After a gene is transcribed into RNA, modifications can occur to the subunits or “bases” that … Continue reading → #news MORE
coli enzyme synthesizing ribosomal RNA that shift it between turbo- and slow-modes depending on the bacteria’s growth rate Credit: Murakami Laboratory, Penn State The enzyme that makes RNA from a DNA template is altered to slow the production of ribosomal RNA (rRNA), the […]. MORE
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus MORE
RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering. MORE
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA … Continue reading → Business Wire MORE
The companies said that patients treated with their experimental drug BIIB080 had reductions in a protein called tau, which research indicates is tied to Alzheimer's but isn't yet proven to impact the course of the disease MORE
San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for neurodegenerative, neuromuscular and retinal diseases MORE
The company aims to make RNA molecules visible and druggable – opening the door to study RNA-based diseases MORE
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech to identify and advance novel RNA-targeted small molecule therapeutics MORE
Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. News R&D Flagship Pioneering Laronde Moderna rna MORE
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules MORE
Key Highlights: Expand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum, Arrakis, PTC Bio & Expansion Therapeutics. MORE
Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in RNA … Continue reading → Business Wire MORE
What The Study Did: Researchers compared the association between symptoms and SARS-CoV-2 RNA levels in children and adults. Authors: Erin Chung, M.D., of the University of Washington School of Medicine in Seattle, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link [link] (doi:10.1001/jamapediatrics.2021.2025) Editor’s Note: The […]. MORE
An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research MORE
RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins MORE
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs MORE
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit. MORE
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing MORE
Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins. MORE
MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD CAMBRIDGE, Mass.–(BUSINESS MORE
?Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade MORE
RNA Related Topics Bio Pharma Dive
MAY 10, 2021
Laronde comes equipped with $50 million in funding from Flagship Pioneering and a goal to upend how diseases are treated with long-lasting RNA medicines
XTalks
SEPTEMBER 13, 2021
billion deal will see the companies use ProQR’s proprietary Axiomer RNA editing platform technology to advance editing oligonucleotide-based therapeutics toward clinical development and commercialization.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JULY 6, 2021
The biotech's decision to pause testing of a cystic fibrosis drug is the latest reminder of the difficulty of delivering RNA medicines into the lungs
Bio Pharma Dive
SEPTEMBER 8, 2021
The company, which focuses on self-replicating RNA, comes equipped with $40 million from Apple Tree Partners and a stamp of approval from the former research head at Biogen
Bio Pharma Dive
AUGUST 30, 2021
Just a few months out of stealth mode, Laronde and its "endless RNA" technology have caught the attention of well-known investors like Fidelity, T. Rowe Price Associates and Invus
Bio Pharma Dive
SEPTEMBER 9, 2021
An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research
Bio Pharma Dive
JANUARY 6, 2021
The companies' pact is the latest addition to a growing list of deals involving startups developing chemical drugs to target RNA molecules
BioSpace
AUGUST 4, 2021
RNA caught the public’s imagination in the form of mRNA vaccines against COVID-19, but RNA can be used in other ways, too, to make therapeutic proteins
Scienmag
JANUARY 22, 2021
coli enzyme synthesizing ribosomal RNA that shift it between turbo- and slow-modes depending on the bacteria’s growth rate Credit: Murakami Laboratory, Penn State The enzyme that makes RNA from a DNA template is altered to slow the production of ribosomal RNA (rRNA), the […].
Pharma Phorum
MAY 12, 2021
UK biotech MiNA Therapeutics has signed up another big pharma partner for its small activating RNA (saRNA) platform, which upregulates the activity of proteins, with Eli Lilly the latest to get in on the action. . News R&D Eli Lilly MiNA Therapeutics partnering rna RNA-based drugs
Pharma Phorum
MAY 14, 2021
Biogen has made a further push into RNA-based drug discovery via a collaboration with Envisagenics, which applies artificial intelligence RNA sequencing data to discover new drug targets and therapeutics. Cambridge, Massachusetts-based Envisagenics focuses on using AI to analyse errors in RNA splicing, a process in which a precursor form of messenger RNA (mRNA) – which is used as a template for protein synthesis in cells – is transformed into a mature form.
Pharma Phorum
AUGUST 31, 2021
Just a few months after breaking cover with its new take on RNA therapeutics, Laronde has raised an impressive $440 million in second-round financing backed by Flagship Pioneering – which was behind the founding of mRNA specialist Moderna. News R&D Flagship Pioneering Laronde Moderna rna
Pharma Phorum
OCTOBER 5, 2020
The only industry-led meeting showcasing the recent development of RNA editing mechanisms and dedicated to realizing the research and therapeutics opportunity of RNA editing as quickly as possible. The post 2nd RNA Editing Summit 2020 appeared first on.
BioTech 365
SEPTEMBER 29, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sequencing multiple RNA base modifications simultaneously: A new era of RNA biology.After a gene is transcribed into RNA, modifications can occur to the subunits or “bases” that … Continue reading → #news
Scienmag
APRIL 14, 2021
Credit: Surajit Chatterjee To better understand how RNA in bacteria gives rise to protein–and along the way, target these processes in the design of new antibiotics–researchers are turning their attention to the unique way this process happens in bacteria.
Scienmag
JULY 8, 2021
Oncotarget published “Transcriptome analyses of urine RNA reveal tumor markers for human bladder cancer: validated amplicons for RT-qPCR-based detection” which reported that in case of bladder cancer, […].
Pharma Phorum
SEPTEMBER 1, 2020
The world of drug discovery and chemical probes is still protein-centric and developing highly selective small molecules targeting RNA is often considered to be an insurmountable challenge. Why You Should Attend the RNA- Targeted Drug Discovery Summit.
BioSpace
AUGUST 29, 2021
?Laronde has managed to secure as much as $440 million from a Series B financing round to support as many as 100 Endless RNA (eRNA) products and drug programs over the next decade
BioTech 365
OCTOBER 11, 2021
BioTech 365
SEPTEMBER 13, 2021
RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “RNA Analysis/Transcriptomics – Global Market Trajectory & Analytics” report has been added to ResearchAndMarkets.com’s offering.
Scienmag
SEPTEMBER 29, 2021
Bio Pharma Dive
JULY 27, 2021
The companies said that patients treated with their experimental drug BIIB080 had reductions in a protein called tau, which research indicates is tied to Alzheimer's but isn't yet proven to impact the course of the disease
BioSpace
SEPTEMBER 8, 2021
?The partnership combines the companies' resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner
Pharma Phorum
SEPTEMBER 28, 2021
Key Highlights: Expand your knowledge of the RNA landscape by gaining exclusive insights and data-driven updates to streamline the success of your RNA candidates from leaders of the field such as Nymirum, Arrakis, PTC Bio & Expansion Therapeutics.
BioTech 365
AUGUST 31, 2021
HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India HDT Bio Corp and Gennova Complete Phase 1 Trial of COVID-19 RNA Vaccine in India Vaccine Would Be India’s First Indigenous RNA Vaccine, Exemplifying HDT … Continue reading → Business Wire
Scienmag
AUGUST 4, 2020
Led by Boyce Thompson Institute’s Andrew Nelson, four partners will identify RNA modifications and develop resources that may lead to hardier crops Credit: Photo credit: Anna Nelson Dittrich ITHACA, NY, August 4, 2020 — RNA perform a variety of functions in cells, helping with everything from regulating genes to building proteins.
BioSpace
DECEMBER 21, 2020
Skyhawk Therapeutics and Vertex Pharmaceuticals inked a strategic research collaboration and licensing deal focused on developing novel small molecules that modulate RNA splicing
BioTech 365
SEPTEMBER 21, 2021
MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD MPM Expands its Team with the Appointment of RNA Expert and Leading Biotech Executive Pete Smith, PhD CAMBRIDGE, Mass.–(BUSINESS
BioSpace
SEPTEMBER 22, 2020
RNA-binding proteins are emerging as the next generation of molecular medicine
Pharma Phorum
APRIL 30, 2021
With RNA-based technology hitting the headlines in recent months due to its use in Covid vaccines, he also discusses the version of it that Galapagos uses and how it can produce compounds that might alter the course of a disease.
BioTech 365
OCTOBER 14, 2021
Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA … Continue reading → Business Wire
BioSpace
JANUARY 5, 2021
Durham, North Carolina-based Ribometrix announced a strategic collaboration deal with Genentech to identify and advance novel RNA-targeted small molecule therapeutics
Scienmag
JULY 2, 2021
Scienmag
JUNE 11, 2021
What The Study Did: Researchers compared the association between symptoms and SARS-CoV-2 RNA levels in children and adults. Authors: Erin Chung, M.D., of the University of Washington School of Medicine in Seattle, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link [link] (doi:10.1001/jamapediatrics.2021.2025) Editor’s Note: The […].
BioTech 365
SEPTEMBER 20, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: RNA-targeting enzyme expands the CRISPR toolkit.Researchers at MIT’s McGovern Institute for Brain Research have discovered a bacterial enzyme that they say could expand scientists’ CRISPR toolkit, making … Continue reading → #news
BioSpace
DECEMBER 13, 2020
San Diego-based Locanabio secured $100 million in a Series B financing round that will be used to advance the company’s portfolio of novel RNA-targeted gene therapies for neurodegenerative, neuromuscular and retinal diseases
BioTech 365
AUGUST 25, 2021
Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Cardior Raises €64M Series B to Advance Clinical Pipeline of RNA Therapeutics to Treat Cardiac Disease Oversubscribed round enables late-stage clinical development of lead … Continue reading → Business Wire
Scienmag
APRIL 13, 2021
BioSpace
JULY 27, 2021
That's the groundbreaking connection AI-driven RNA therapeutics has given us, according to Deep Genomics Founder and CEO Brendan Frey "For the first time in history, medicine has become information."
BioTech 365
SEPTEMBER 13, 2021
16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com 16S Ribosomal RNA (16S rRNA) Drugs in Development, 2021 Pipeline Landscape Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “16S Ribosomal RNA (16S rRNA) – Drugs in Development, 2021” … Continue reading → Business Wire
BioTech 365
SEPTEMBER 13, 2021
Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com Growth Opportunities in RNA Therapeutics, Cancer Therapeutics & Diagnostics, and Lung Health Markets, 2021 Report – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Growth Opportunities in RNA … Continue reading → Business Wire
211 
Let's personalize your content